TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 24743062

Group type: EXPERIMENTAL
Intervention: Multidisciplinary intervention
Number of subjects: 285

Group type: COMPARATOR
Intervention: Brief intervention
Number of subjects: 285

Group type: EXPERIMENTAL
Intervention: Multiple somatic symptoms (measured by SCL‐SOM)
Number of subjects: 285

Group type: EXPERIMENTAL
Intervention: Sickness absence (SA)
Number of subjects: 285

Group type: EXPERIMENTAL
Intervention: Return to work (RTW)
Number of subjects: 285
Study: 22727935

Group type: EXPERIMENTAL
Intervention: OFD+NHA
Number of subjects: 30

Group type: COMPARATOR
Intervention: OFD
Number of subjects: 30
Study: 19437334

Group type: EXPERIMENTAL
Intervention: Aspirin 160 mg per day for 7‐10 days
Number of subjects: 37

Group type: COMPARATOR
Intervention: Placebo for 7‐10 days
Number of subjects: 37
Study: 18158077

Group type: EXPERIMENTAL
Intervention: Pitavastatin 2 mg/d
Number of subjects: 268

Group type: COMPARATOR
Intervention: Atorvastatin 10 mg/d
Number of subjects: 268
Study: 16235010

Group type: EXPERIMENTAL
Intervention: Acetyl-L-carnitine
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control (untreated girls with Rett syndrome)
Number of subjects: 10
Study: 12098152

Group type: EXPERIMENTAL
Intervention: Isokinetic knee movements at speeds of 60 degrees/s, 180 degrees/s, and 300 degrees/s
Number of subjects: 20
Study: 10409530

Group type: EXPERIMENTAL
Intervention: sotalol 80 mg twice daily
Number of subjects: 41

Group type: COMPARATOR
Intervention: atenolol 50 mg once daily
Number of subjects: 41
Study: 7650808

Group type: EXPERIMENTAL
Intervention: Paternal white blood cell immunization (published studies)
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: Paternal white blood cell immunization (individual patient data)
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: Paternal white blood cell immunization (unpublished trials)
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: Paternal white blood cell immunization (published studies, random treatment effect model)
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: Paternal white blood cell immunization (individual patient data, random treatment effect model)
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: Paternal white blood cell immunization (unpublished trials, random treatment effect model)
Number of subjects: 202
Study: 1692988

Group type: EXPERIMENTAL
Intervention: Galanin (Gal) plus growth hormone‐releasing hormone (GHRH)
Number of subjects: 15

Group type: COMPARATOR
Intervention: GHRH alone
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Pyridostigmine (PD) plus Gal
Number of subjects: 15

Group type: COMPARATOR
Intervention: Gal alone
Number of subjects: 15
Study: 7417900

Group type: EXPERIMENTAL
Intervention: Topical antibiotic spray (neomycin sulfate, polymyxin B sulfate, zinc bacitracin)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Placebo spray
Number of subjects: 150
Study: 30711459

Group type: EXPERIMENTAL
Intervention: Freeze-only strategy (n = 391)
Number of subjects: 782

Group type: COMPARATOR
Intervention: Fresh embryo transfer strategy (n = 391)
Number of subjects: 782

Group type: EXPERIMENTAL
Intervention: Both strategies
Number of subjects: 782
Study: 28198084

Group type: EXPERIMENTAL
Intervention: Intravenous iron
Number of subjects: 196

Group type: COMPARATOR
Intervention: Oral iron
Number of subjects: 196
Study: 22930789

Group type: EXPERIMENTAL
Intervention: Atomoxetine (target dose: 1.2 mg/kg per day)
Number of subjects: 125

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 125
Study: 23646472

Group type: EXPERIMENTAL
Intervention: Guizhi Fuling Decoction (GFD)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Routine treatment
Number of subjects: 72
Study: 22195356

Group type: EXPERIMENTAL
Intervention: Valsartan (angiotensin II receptor blocker)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Amlodipine (control)
Number of subjects: 0
Study: 19469697

Group type: EXPERIMENTAL
Intervention: brimonidine P 0.15%
Number of subjects: 1596

Group type: EXPERIMENTAL
Intervention: brimonidine P 0.1%
Number of subjects: 1596
Study: 17531918

Group type: EXPERIMENTAL
Intervention: Left-ventricular assist device (LVAD) support
Number of subjects: 25

Group type: COMPARATOR
Intervention: Inotropic drugs
Number of subjects: 25

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 25
Study: 15238590

Group type: EXPERIMENTAL
Intervention: Enoxaparin
Number of subjects: 10027

Group type: COMPARATOR
Intervention: Unfractionated heparin
Number of subjects: 10027
Study: 11598594

Group type: EXPERIMENTAL
Intervention: Resistance training (30 to 45 minutes a day, 3 days per week, using 15 different resistance exercises)
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Resistance training
Number of subjects: 67

Group type: COMPARATOR
Intervention: Control (sedentary, <2 hours of exercise per week)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Control
Number of subjects: 67
Study: 9537703

Group type: EXPERIMENTAL
Intervention: Forced air warming
Number of subjects: 25

Group type: COMPARATOR
Intervention: Passive heat preservation techniques
Number of subjects: 25
Study: 7985599

Group type: EXPERIMENTAL
Intervention: Pindolol, Propranolol, Metoprolol, Atenolol, Hydrochlorothiazide
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Captopril
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Beta-adrenergic blockade without intrinsic sympathomimetic activity and Hydrochlorothiazide
Number of subjects: 65
Study: 2672774

Group type: EXPERIMENTAL
Intervention: Sucrose (45 g, 9% of total daily energy) added to diet
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Aspartame (162 mg) added to diet
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (usual diet without added sucrose or aspartame)
Number of subjects: 0
Study: 338390

Group type: EXPERIMENTAL
Intervention: Baclofen
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 31630479

Group type: EXPERIMENTAL
Intervention: Apixaban 10 mg twice daily for seven days followed by 5 mg twice daily for six months
Number of subjects: 300

Group type: COMPARATOR
Intervention: Dalteparin (200 IU/kg for one month followed by 150 IU/kg once daily)
Number of subjects: 300
Study: 31196815

Group type: EXPERIMENTAL
Intervention: Dapagliflozin 10 mg once daily
Number of subjects: 17160

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17160
Study: 28298543

Group type: EXPERIMENTAL
Intervention: Nutrition education program in Karimganj
Number of subjects: 2400
Study: 25697717

Group type: EXPERIMENTAL
Intervention: 5-mm injection depth of insulin lispro (0.25 U/kg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: 8-mm injection depth of insulin lispro (0.25 U/kg)
Number of subjects: 0
Study: 23978642

Group type: EXPERIMENTAL
Intervention: Low-dose salbutamol (1μg)
Number of subjects: 12
Study: 21356110

Group type: COMPARATOR
Intervention: MEDI-528 (0.3, 1, 3 mg/kg)
Number of subjects: 36

Group type: COMPARATOR
Intervention: MEDI-528 (50 mg)
Number of subjects: 36
Study: 19512882

Group type: EXPERIMENTAL
Intervention: Air LORT
Number of subjects: 360

Group type: COMPARATOR
Intervention: Saline LORT
Number of subjects: 360

Group type: EXPERIMENTAL
Intervention: Absence of initial fluid return
Number of subjects: 360
Study: 17088125

Group type: EXPERIMENTAL
Intervention: Modified allergen extracts containing 50% Dermatophagoides pteronyssinus and 50% Dermatophagoides farinae
Number of subjects: 64

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Modified allergen extracts
Number of subjects: 64
Study: 12970701

Group type: EXPERIMENTAL
Intervention: Reminder letter and confirmation slip
Number of subjects: 232

Group type: COMPARATOR
Intervention: No reminder
Number of subjects: 232

Group type: EXPERIMENTAL
Intervention: Social deprivation effect
Number of subjects: 232
Study: 11249629

Group type: EXPERIMENTAL
Intervention: Transgenic recombinant human antithrombin III (rhAT-III)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 9138658

Group type: EXPERIMENTAL
Intervention: Wheat bran fiber (2.0 or 13.5 g/day)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Calcium carbonate (250 or 1500 mg/day)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo (2.0 g of wheat bran fiber plus 250 mg of calcium carbonate during 3-month run-in)
Number of subjects: 100
Study: 8222940

Group type: EXPERIMENTAL
Intervention: Ultrasonic root canal instrumentation
Number of subjects: 432

Group type: COMPARATOR
Intervention: Hand root canal instrumentation
Number of subjects: 432
Study: 3899370

Group type: EXPERIMENTAL
Intervention: Metoprolol 50 mg b.i.d.
Number of subjects: 31

Group type: COMPARATOR
Intervention: Clonidine 50 micrograms b.i.d.
Number of subjects: 31
Study: 31420735

Group type: EXPERIMENTAL
Intervention: Stressful training with insufficient recovery (NFOR)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Normal training (CON)
Number of subjects: 16
Study: 29154553

Group type: EXPERIMENTAL
Intervention: Female‐Specific Cognitive Behavioral Therapy (FS‐CBT)
Number of subjects: 99

Group type: COMPARATOR
Intervention: Gender‐neutral Cognitive Behavioral Therapy (GN‐CBT)
Number of subjects: 99
Study: 25886088

Group type: EXPERIMENTAL
Intervention: Imiquimod 5% cream combined with salicylic acid 15%
Number of subjects: 86

Group type: COMPARATOR
Intervention: Cryotherapy with liquid nitrogen
Number of subjects: 86
Study: 23836239

Group type: EXPERIMENTAL
Intervention: Tourniquet use throughout the procedure (operative tourniquet group)
Number of subjects: 71

Group type: COMPARATOR
Intervention: Tourniquet use only during cementation (cementation tourniquet group)
Number of subjects: 71
Study: 22350327

Group type: EXPERIMENTAL
Intervention: Educational software for childbirth education for 6-8 weeks
Number of subjects: 150

Group type: COMPARATOR
Intervention: Control group (no educational intervention)
Number of subjects: 150
Study: 20546013

Group type: EXPERIMENTAL
Intervention: Low CHO
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: High CHO
Number of subjects: 6

Group type: COMPARATOR
Intervention: Control
Number of subjects: 6
Study: 18794647

Group type: EXPERIMENTAL
Intervention: 1.5 mg/kg MDMA
Number of subjects: 15
Study: 12568145

Group type: EXPERIMENTAL
Intervention: Electro-acupuncture (EA)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Superficial needle insertion (control)
Number of subjects: 30
Study: 9735576

Group type: EXPERIMENTAL
Intervention: Individualized motivational brief intervention
Number of subjects: 348

Group type: COMPARATOR
Intervention: No-treatment control condition
Number of subjects: 348

Group type: COMPARATOR
Intervention: Natural history comparison group
Number of subjects: 348
Study: 7981177

Group type: EXPERIMENTAL
Intervention: Highly oxidized oil
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Medium-oxidized oil
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control corn oil
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control corn oil vs. Highly oxidized oil
Number of subjects: 0
Study: 2741976

Group type: EXPERIMENTAL
Intervention: Propranolol (80 mg, four times daily)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Nifedipine (20 mg, four times daily)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Nifedipine (10 mg sublingually)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Propranolol (0.1 mg/kg intravenously)
Number of subjects: 24
Study: 31141968

Group type: EXPERIMENTAL
Intervention: Rehydration for 2 hours
Number of subjects: 8

Group type: COMPARATOR
Intervention: Hypohydrated state
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Rehydration trial
Number of subjects: 8

Group type: COMPARATOR
Intervention: Hypohydrated trial
Number of subjects: 8
Study: 29390272

Group type: EXPERIMENTAL
Intervention: SQJZ herbal formula
Number of subjects: 240

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 240
Study: 26046622

Group type: EXPERIMENTAL
Intervention: Minimalist footwear (MFW) and gait-retraining intervention (n = 13)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Minimalist footwear (MFW)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Gait-retraining intervention
Number of subjects: 23
Study: 23811974

Group type: EXPERIMENTAL
Intervention: Patients with MS
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Female patients with MS
Number of subjects: 48

Group type: COMPARATOR
Intervention: Male control subjects
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Male patients with MS
Number of subjects: 48
Study: 21466679

Group type: EXPERIMENTAL
Intervention: Percutaneous vertebroplasty (PV)
Number of subjects: 180

Group type: COMPARATOR
Intervention: Sham intervention
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: PV
Number of subjects: 180
Study: 19793962

Group type: EXPERIMENTAL
Intervention: Adaptation to second-order faces with happy and sad expressions using local directions of moving random dots on a static-dot background.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Adding static random dots to first-order faces to match the background of adapting motion faces.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Real-face adaptation with added noise that matched correlation statistics of real faces or natural images.
Number of subjects: 0
Study: 16931609

Group type: EXPERIMENTAL
Intervention: Glutamine-enriched enteral nutrition (0.3 g/kg/d)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Control group (isonitrogenous placebo supplementation - alanine)
Number of subjects: 102
Study: 15451912

Group type: EXPERIMENTAL
Intervention: Fasting insulin levels, BMI, waist-to-hip ratio
Number of subjects: 559

Group type: EXPERIMENTAL
Intervention: Systolic and diastolic blood pressures
Number of subjects: 559

Group type: EXPERIMENTAL
Intervention: Two-hour postload plasma glucose (2-h PG), serum insulin, fasting plasma glucose
Number of subjects: 559

Group type: EXPERIMENTAL
Intervention: Serum total cholesterol and triglycerides
Number of subjects: 559

Group type: EXPERIMENTAL
Intervention: Combination of systolic and diastolic blood pressure
Number of subjects: 559

Group type: EXPERIMENTAL
Intervention: Urinary albumin excretion rate
Number of subjects: 559
Study: 11163499

Group type: EXPERIMENTAL
Intervention: Accelerated hyperfractionation alone (Arm A)
Number of subjects: 231

Group type: EXPERIMENTAL
Intervention: Accelerated hyperfractionation with DFMO (Arm B)
Number of subjects: 231

Group type: COMPARATOR
Intervention: Standard fractionated irradiation (Arm C)
Number of subjects: 231

Group type: COMPARATOR
Intervention: Standard fractionated irradiation with DFMO (Arm D)
Number of subjects: 231
Study: 9255764

Group type: EXPERIMENTAL
Intervention: Skinner herpes simplex vaccine (NFU.Ac.HSV‐1(S‐)MRC) administered at 0, 1, and 2 months
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Skinner herpes simplex vaccine (NFU.Ac.HSV‐1(S‐)MRC)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Skinner herpes simplex vaccine (NFU.Ac.HSV‐1(S‐)MRC
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 7685425

Group type: EXPERIMENTAL
Intervention: Verapamil (80 mg, four doses orally starting the night before ESWL)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control (no medication)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Verapamil
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control
Number of subjects: 24
Study: 31647902

Group type: EXPERIMENTAL
Intervention: Gastric Electrical Stimulation (GES) ON (14 Hz, 5 mA, pulses of 330 μs)
Number of subjects: 172

Group type: COMPARATOR
Intervention: Control (GES OFF)
Number of subjects: 172

Group type: EXPERIMENTAL
Intervention: Gastric Electrical Stimulation (GES) ON
Number of subjects: 172
Study: 29196161

Group type: EXPERIMENTAL
Intervention: Kinesio taping over upper trapezius (UT)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Kinesio taping over middle trapezius (MT)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Kinesio taping over lower trapezius (LT)
Number of subjects: 54
Study: 28370401

Group type: EXPERIMENTAL
Intervention: High-dose cyclophosphamide (2 g/m2 daily on days 1 and 2) plus G-CSF and pre-emptive/rescue plerixafor
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: High-dose cyclophosphamide (2 g/m2 daily on days 1 and 2) plus G-CSF
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: High-dose cyclophosphamide (2 g/m2 daily on days 1 and 2)
Number of subjects: 30
Study: 26510013

Group type: EXPERIMENTAL
Intervention: Nutrition education plus supervised physical activity 3 days/week
Number of subjects: 42

Group type: COMPARATOR
Intervention: Nutrition education only
Number of subjects: 42
Study: 24103532

Group type: EXPERIMENTAL
Intervention: IMSI
Number of subjects: 66
Study: 21716073

Group type: EXPERIMENTAL
Intervention: Dolutegravir 2 mg
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Dolutegravir 10 mg
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Dolutegravir 50 mg
Number of subjects: 35

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study: 19194375

Group type: EXPERIMENTAL
Intervention: Combined cholinergic receptor blockade (scopolamine 4 microg/kg bodyweight intravenously and mecamylamine 5 mg orally)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combined cholinergic receptor blockade
Number of subjects: 0
Study: 16704676

Group type: EXPERIMENTAL
Intervention: Combination of splinting, tendon‐ and nerve‐gliding exercises
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Ultrasound treatment in combination with splinting
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Combination of ultrasound, splinting, tendon‐ and nerve‐gliding exercises
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Combination of splinting, exercise and ultrasound therapy
Number of subjects: 28
Study: 15679252

Group type: EXPERIMENTAL
Intervention: Concurrent chemoradiation with surgery
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Concurrent chemoradiation without surgery
Number of subjects: 0

Group type: COMPARATOR
Intervention: Surgery alone
Number of subjects: 0
Study: 11316542

Group type: EXPERIMENTAL
Intervention: Hfx RT with daily carboplatin/etoposide (50 mg each)
Number of subjects: 195

Group type: COMPARATOR
Intervention: Hfx RT with daily carboplatin/etoposide (30 mg each) and weekend carboplatin/etoposide (100 mg each)
Number of subjects: 195
Study: 9027276

Group type: EXPERIMENTAL
Intervention: Allopurinol (20 mg/kg/day, three 100-mg tablets four times daily for 28 days)
Number of subjects: 187

Group type: COMPARATOR
Intervention: Placebo (three placebo tablets four times daily for 28 days)
Number of subjects: 187

Group type: EXPERIMENTAL
Intervention: Glucantime (20 mg of intramuscular antimony/kg per day for 20 days)
Number of subjects: 187
Study: 8276046

Group type: EXPERIMENTAL
Intervention: Single oral dose of SDZ MKS 492 (40 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Inhaled SDZ MKS 492 (12 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Inhaled SDZ MKS 492 (10 mg and 20 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Inhaled SDZ MKS 492
Number of subjects: 0
Study: 3561330

Group type: EXPERIMENTAL
Intervention: ticarcillin and cefamandole (TC)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: ticarcillin and cefamandole with tobramycin (TCT)
Number of subjects: 100
Study: 29716471

Group type: EXPERIMENTAL
Intervention: Circle of Security (COS) group intervention
Number of subjects: 52

Group type: COMPARATOR
Intervention: Standard-mother-infant treatment (TAU)
Number of subjects: 52
Study: 26935334

Group type: EXPERIMENTAL
Intervention: Levofloxacin inhalation solution (LIS) 240mg twice daily for 28 days
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Levofloxacin inhalation solution (LIS)
Number of subjects: 88
Study: 24694461

Group type: EXPERIMENTAL
Intervention: Bleeding after PCI
Number of subjects: 4329

Group type: COMPARATOR
Intervention: No bleeding
Number of subjects: 4329

Group type: EXPERIMENTAL
Intervention: Non-access-site bleeding
Number of subjects: 4329

Group type: EXPERIMENTAL
Intervention: Access-site bleeding
Number of subjects: 4329
Study: 22830446

Group type: EXPERIMENTAL
Intervention: Caseload midwifery
Number of subjects: 2314

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 2314
Study: 20378601

Group type: EXPERIMENTAL
Intervention: Sitaxsentan (100 mg·day(‐1) for 7 days)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study: 18803046

Group type: EXPERIMENTAL
Intervention: Intensive insulin therapy
Number of subjects: 22
Study: 16533589

Group type: EXPERIMENTAL
Intervention: Culturally tailored genetic counseling (CTGC)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Standard genetic counseling (SGC)
Number of subjects: 54
Study: 14640991

Group type: EXPERIMENTAL
Intervention: GH (0.88+/‐0.13 mg)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: GH+acipimox 250 mg b.i.d.
Number of subjects: 10

Group type: COMPARATOR
Intervention: Acipimox b.i.d. (no GH)
Number of subjects: 10
Study: 10985874

Group type: EXPERIMENTAL
Intervention: Disposable automatic lancing devices with trigger‐linked lancet movement
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Devices with a blade
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Devices producing blood volumes > 50 microl
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Two of the devices
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: All disposable automatic lancing devices
Number of subjects: 50
Study: 8853083

Group type: EXPERIMENTAL
Intervention: 6 to 7% sevoflurane in 66% nitrous oxide/28% oxygen by face mask until tracheal intubation (treatment 1)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 6 to 7% sevoflurane without nitrous oxide to tracheal intubation (treatment 2)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 6 to 7% sevoflurane in 66% nitrous oxide/28% oxygen by face mask until laryngeal mask airway insertion (treatment 3)
Number of subjects: 20
Study: 1535877

Group type: EXPERIMENTAL
Intervention: High-dose ionic contrast medium (diatrizoate sodium)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: High-dose nonionic contrast medium (iohexol)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Low-dose nonionic contrast medium (iohexol)
Number of subjects: 150
Study: 6526201

Group type: EXPERIMENTAL
Intervention: Isosorbide Dinitrate Ointment (ISDN-O): 300 mg daily
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 30878411

Group type: EXPERIMENTAL
Intervention: Low-dose nebulized epinephrine (0.1 mg/kg; maximum 1 mg)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Conventional dose nebulized epinephrine (0.5 mg/kg; maximum 5 mg)
Number of subjects: 84
Study: 29205440

Group type: EXPERIMENTAL
Intervention: Structured reflection procedure
Number of subjects: 42

Group type: COMPARATOR
Intervention: Alternative diagnoses (control group)
Number of subjects: 42